ClinicalTrials.gg
CompletedNCT06976346Updated May 16, 2025

Relative Bioavailability Study of HRG2010 in Healthy Subjects

A Phase 1 interventional study of HRG2010 Capsule, Sinemet®, Madopar® in Parkinson's Disease, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Diagnostic

From the registry’s dates

  • Registered 3 years 7 months after the study started (first participant enrolled Sep 2021, registered May 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 279 studies in Parkinson Disease with a site in China — 129 open to participants now, 136 under way, 3 of them phase 3. Parkinson Disease · China.

Enrollment
172nd of 211
16 · median 48
Started
2021
with 20 others
Phase 1
39 of 279
22 open now
Registered
210th of 279
by date

Among the 279 studies in Parkinson Disease with a site in China, this one is the 172nd largest by enrollment of the 211 interventional ones that give a count, is one of 21 that started in 2021, is one of 39 in phase 1, and was the 210th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

129 of the 279 studies in Parkinson Disease with a site in China are open now. Recruiting first, the newest first:

124 more — sign in →

All 129 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 279 studies in Parkinson Disease with a site in China, or all of them as a file.
02

Study summary

This is a single-center, randomized, open-label, four-period, crossover study. Primary Objective:

  1. To evaluate the pharmacokinetic characteristics of healthy subjects after a single oral dose of HRG2010 capsules at dose 1 and dose 2 under fasting conditions, and to compare these with the pharmacokinetic characteristics of Carbidopa/Levodopa Extended-Release Tablets (Sinemet®) and Benserazide/Levodopa Tablets (Madopar®).

    Secondary Objective

  2. To assess safety following administration.
03

Conditions studied

  • Parkinson's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male or female between the ages of 18 and 45 years, inclusive.
  2. At least 50.0 kg for male subjects, 45.0 kg for female subjects, with a (BMI) between 19.0-26.0 kg/m2, inclusive (BMI = weight/height2).
  3. Prior to screening, during the trial, and for 6 months after the trial, subjects (including male subjects) must not have plans to conceive and must voluntarily adopt effective measures.
  4. Subjects who could understand the nature, significance, potential benefits, inconvenience, and potential risks of the study, understand the procedures and methods, be willing to complete the trial strictly following the protocol, and voluntarily sign the .

Exclusion criteria

Exclusion Criteria:

  1. Subjects with history of drug or food allergies.
  2. Subjects with a history of diseases related to the circulatory, endocrine, nervous, digestive, respiratory, hematolymphatic, immune, mental, skin, bone, muscle, urogenital, mucosal, and metabolic systems, who are deemed by the investigator to be unsuitable for inclusion in this study.
  3. Subjects with a history of glaucoma.
  4. Use of any medication within 14 days prior to dosing.
  5. Subjects who have taken any clinical products or participated in the clinical research of medical devices within 3 months before the trial, or plan to participate in other clinical trials during the study.
  6. Subjects who have donated blood or experienced blood loss greater than 300 mL, or have received a blood transfusion or used blood products within 3 months prior to screening, or plan to donate blood during the trial or within 1 month after the trial ends.
  7. Subjects who had undergone major trauma surgery within 3 months before the screening, or planned a surgery during the study.
  8. Subjects who take more than 5 cigarettes per day on average within 3 months prior to the study or do not agree to prohibit smoking during the study.
  9. Drinking frequently within 6 months before the trial, meaning 14 units of alcohol per week(1 unit = 360 mL beer or 45 mL of 40% spirits, or 150 mL wine of 12% spirits), or disagree with the prohibition of alcohol during the study.
  10. Clinical significance in clinical laboratory tests (chemistry, hematology, urinalysis, coagulation function).
  11. Clinical significance in vital signs, physical examination, 12 lead-.
  12. Positive results in any one of virus surface antigen, virus antibody, antibody or syphilis serum reagin test.
  13. Female who are pregnant or breastfeeding.
  14. Breath test for alcohol > 0.0 mg /mL.
  15. Subjects who were positive in drug abuse or had a history of drug abuse.
  16. Difficulty in venous blood collection or unable to tolerate venipuncture or a history of fainting due to needle or blood phobia.
  17. Subjects with swallowing difficulties, or those with special dietary requirements that prevent them from adhering to a unified diet.
  18. Unable to complete the study due to personal reasons or other factors considered by the investigator as unsuitable to participate in the study (such as inability to understand the study requirements, poor compliance, etc.).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Sequence A

    Period 1: HRG2010 dose 1 Period 2: HRG2010 dose 2 Period 3: Sinemet® Period 4: Madopar®

    Drug: HRG2010 Capsule, Sinemet®, Madopar®

  • Experimental
    Sequence B

    Period 1: HRG2010 dose 2 Period 2: Madopar® Period 3: HRG2010 dose 1 Period 4: Sinemet®

    Drug: HRG2010 Capsule, Sinemet®, Madopar®

  • Experimental
    Sequence C

    Period 1: Sinemet® Period 2: HRG2010 dose 1 Period 3: Madopar® Period 4: HRG2010 dose 2

    Drug: HRG2010 Capsule, Sinemet®, Madopar®

  • Experimental
    Sequence D

    Period 1: Madopar® Period 2: Sinemet® Period 3: HRG2010 dose 2 Period 4: HRG2010 dose 1

    Drug: HRG2010 Capsule, Sinemet®, Madopar®

Interventions

  • DrugHRG2010 Capsule, Sinemet®, Madopar®

    In each period under fasting conditions, subjects received oral administration of either HRG2010 Capsule dose 1, HRG2010 Capsule dose 2, Sinemet®, or Madopar®.

06

What researchers measure

Primary outcomes

  1. Cmax: Maximum plasma concentration. Blood samples will be collected.

    Time frame: From 0 hour predose up to 12 hours postdose

  2. AUC0-t: Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration. Blood samples will be collected.

    Time frame: From 0 hour predose up to 12 hours postdose

  3. AUC0-∞: Area under the plasma concentration-time curve from time 0 to infinity. Blood samples will be collected.

    Time frame: From 0 hour predose up to 12 hours postdose

  4. Tmax: Observed time to reach Cmax. Blood samples will be collected.

    Time frame: From 0 hour predose up to 12 hours postdose

Secondary outcomes

  1. Incidence of treatment emergent AEs (TEAEs)

    Time frame: From Signing of Informed Consent Form (ICF) up to Safety Follow Up (Up to Day 22)

07

Study locations

1 site
  • Shandong Province Qianfoshan Hospital
    Jinan, Shandong 250000, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Oct 2021, 0 months.

Of 127 industry-sponsored phase 1 interventional studies under Parkinson Disease, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's 0 months is below that.

Counting every sponsor, half of 204 studies reached it within 18 months; a quarter within 5 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2025
First posted
May 16, 2025
StartActual
Sep 10, 2021
Primary completionActual
Oct 7, 2021
CompletionActual
Oct 7, 2021
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06976346
Responsible party
Sponsor
First posted
May 16, 2025
Start date
Sep 10, 2021
Primary completion
Oct 7, 2021
Completion
Oct 7, 2021
Last update
May 16, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion